You searched for: idarucizumab (Maltesiska - Engelska)

is-sustanza attiva hi idarucizumab.
the active substance is idarucizumab.

praxbind fih is-sustanza attiva idarucizumab.
praxbind contains the active substance idarucizumab.

idarucizumab huwa aġent riversiv speċifiku għal dabigatran.
idarucizumab is a specific reversal agent for dabigatran.

kull kunjett ta' 50 ml fih 2.5 g idarucizumab.
each vial contains 2.5 g idarucizumab in 50 ml.

dan jissuġġerixxi li idarucizumab ma għandu ebda effett protrombotiku.
this suggests that idarucizumab has no prothrombotic effect.

idarucizumab waħdu ma wera ebda effett prokoagulanti mkejjel bħala etp.
idarucizumab alone has shown no procoagulant effect measured as etp.

praxbind 2.5 g/50 ml soluzzjoni għal injezzjoni/infużjoni idarucizumab
praxbind 2.5 g/50 ml solution for injection/infusion idarucizumab

għalhekk, idarucizumab ma jaqlibx lura l-effetti ta' antikoagulanti oħrajn.
thus idarucizumab will not reverse the effects of other anticoagulants.

ma sarux studji li jivvalutaw l-effetti riproduttivi potenzjali ta' idarucizumab.
studies to assess the potential reproductive effects of idarucizumab have not been performed.

praxbind 2.5 g/50 ml soluzzjoni għall-injezzjoni/infużjoni idarucizumab
praxbind 2.5 g/50 ml solution for injection/infusion idarucizumab

idarucizumab jeħel speċifikament ma' dabigatran u jaqleb lura l-effetti antikoagulanti tiegħu.
idarucizumab binds specifically to dabigatran and reverses its anticoagulant effect.

effett ta' idarucizumab fuq l-espożizzjoni u l-attività antikoagulanti ta' dabigatran
effect of idarucizumab on the exposure and anticoagulant activity of dabigatran

mhuwiex mistenni impatt ta' indeboliment tal-fwied fuq il-farmakokinetika ta' idarucizumab.
an impact of hepatic impairment on the pharmacokinetics of idarucizumab is not expected.

l-indeboliment tal-kliewi ma kellux impatt fuq l-effett riversiv ta' idarucizumab.
renal impairment did not impact the reversal effect of idarucizumab.

ma ġew rilevati ebda antikorpi anti-idarucizumab f'dawn is-suġġetti qabel it-tieni għoti.
no anti-idarucizumab antibodies were detected in these subjects prior to the second administration.

f'suġġett wieħed, ġew rilevati antikorpi anti-idarucizumab li feġġew wara l-kura wara t-tieni għoti.
in one subject, treatment-emergent anti- idarucizumab antibodies were detected after the second administration.

idarucizumab jeħel bis-saħħa u speċifikament ma' dabigatran u mal-metaboliti tiegħu u jinnewtralizza l-effetti antikoagulanti tagħhom.
idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect.

barra minn hekk, ma ġie osservat ebda twaħħil ta' idarucizumab mat-tessuti riproduttivi umani fi studju ta' reattività inkroċjata tat-tessuti.
additionally, no idarucizumab binding to human reproductive tissues was observed in a tissue cross-reactivity study.

dan seħħ minn sagħtejn sa 24 siegħa wara l-għoti ta' idarucizumab f'punti ta' żmien ta' ≥ 12 siegħa.
this occurred 2-24 hours after administration of idarucizumab mainly at timepoints ≥12 hours.

24 siegħa wara l-infużjoni ta' idarucizumab, l-għoti mill--ġdid ta' etessilat tad-dabigatran rriżulta f'attività antikoagulanti mistennija.
24 hours after the idarucizumab infusion, re-administration of dabigatran etexilate resulted in expected anticoagulant activity.